Please assess the completion status of the following clinical trial:

Trial Title: Armodafinil for Patients Starting Hepatitis C Virus Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV+ patients medically cleared for IFN/RBV treatment -HIV+ or HIV-~* Speaks English~* Able and willing to give informed consent~* Fecund women: use barrier method of contraception~Exclusion Criteria:~* Untreated and uncontrolled hypertension~* Left ventricular hypertrophy~* Currently taking stimulant medication~* Uncontrolled mental health problems including: MDD, suicidal or homicidal ideation, bipolar disorder, or schizophrenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Armodafinil (Type: EXPERIMENTAL): Active medication
- Sugar pill (Type: PLACEBO_COMPARATOR): Inactive pill, matched to look like active medication

Based on this trial design, predict the completion outcome and termination type (if applicable).